AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 5.88 |
Market Cap | 582.92M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -2.84 |
PE Ratio (ttm) | -3.52 |
Forward PE | n/a |
Analyst | Buy |
Ask | 12.3 |
Volume | 687,463 |
Avg. Volume (20D) | 532,909 |
Open | 11.19 |
Previous Close | 11.04 |
Day's Range | 9.50 - 11.31 |
52-Week Range | 9.50 - 30.19 |
Beta | undefined |
About CGEM
Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody f...
Analyst Forecast
According to 9 analyst ratings, the average rating for CGEM stock is "Buy." The 12-month stock price forecast is $29.5, which is an increase of 194.68% from the latest price.